J Bone Metab.  2014 May;21(2):143-149. 10.11005/jbm.2014.21.2.143.

Physicians' Attitudes to Contemporary Issues on Osteoporosis Management in Korea

• Ha YC
• Lee YK
• Lim YT
• Jang SM
• Shin CS

• KMID: 2241535
• DOI: http://doi.org/10.11005/jbm.2014.21.2.143

Abstract

BACKGROUND
In management of osteoporosis, several concerns here have been raised. The current issue included the utilization of dual energy X-ray absorptiometry (DXA) and fracture-risk assessment (FRAX), screening of vitamin D deficiency and secondary osteoporosis, and long-term use of bisphosphonate and calcium supplements. There was no study on physicians' attitude on these current issues in Korea. Therefore, we investigated the physicians' attitude on these issues by survey.
METHODS
We administered a 30-item questionnaire to all members of Korean Society for Bone and Mineral Research by email survey form. One hundred participants answered the questionnaire. The questionnaire included the questions about the physicians' attitude to current issues and the barriers to osteoporosis treatment in Korea.
RESULTS
Most physicians used bone densitometry devices (99%) and, central DXA was the most accessible device (95%). Eighty-eight percent were aware of FRAX(R), but among them, only 19.3% used it. The main reason for not using FRAX(R) was the lack of time in their proactive (76%). Screening for vitamin D status and secondary osteoporosis was performed by 59% and 52% of the respondents, respectively. The lack of awareness among patients and high costs of medication were perceived as the most important barriers to osteoporosis management in Korea.
CONCLUSIONS
This study provides physicians' perspective to the current issue for diagnostic and treatment of osteoporosis in Korea. To further improve osteoporosis management, educational programs for patients and doctors, and the improvement of reimbursement system should be considered in Korea.

Keyword

Bisphosphonate; Bone densitometry; Calcium; FRAX(R); Osteoporosis; Secondary osteoporosis; Vitamin D

MeSH Terms

Absorptiometry, Photon
Calcium
Surveys and Questionnaires
Densitometry
Electronic Mail
Humans
Korea
Mass Screening
Osteoporosis*
Vitamin D
Vitamin D Deficiency
Calcium
Vitamin D

Figure

• 

  Fig. 1 Device for bone mineral density (BMD) measurement. DXA, dual energy X-ray absorptiometry; QCT, quantitative computed tomography; USG, ultrasonography.

• 

  Fig. 2 Reasons for not using fracture-risk assessment (FRAX).

• 

  Fig. 3 Proportion of screening vitamin D according to department, type of institute, and number of patients.

• 

  Fig. 4 Barriers to osteoporosis treatment in Korea. Multiple answers from one respondent were possible. The proportions are calculated based on the total number of respondents.

Reference

1. Reginster JY, Burlet N. Osteoporosis: a still increasing prevalence. Bone. 2006; 38:S4–S9.

2. Borgström F, Sobocki P, Ström O, et al. The societal burden of osteoporosis in Sweden. Bone. 2007; 40:1602–1609.

3. Salaffi F, Cimmino MA, Malavolta N, et al. The burden of prevalent fractures on health-related quality of life in postmenopausal women with osteoporosis: the IMOF study. J Rheumatol. 2007; 34:1551–1560.

4. Yoon HK, Park C, Jang S, et al. Incidence and mortality following hip fracture in Korea. J Korean Med Sci. 2011; 26:1087–1092.

5. Lee YK, Jang S, Jang S, et al. Mortality after vertebral fracture in Korea: analysis of the National Claim Registry. Osteoporos Int. 2012; 23:1859–1865.

6. Park C, Ha YC, Jang S, et al. The incidence and residual lifetime risk of osteoporosis-related fractures in Korea. J Bone Miner Metab. 2011; 29:744–751.

7. Johansson H, Kanis JA, Oden A, et al. BMD, clinical risk factors and their combination for hip fracture prevention. Osteoporos Int. 2009; 20:1675–1682.

8. Middleton RG, Shabani F, Uzoigwe CE, et al. FRAX and the assessment of the risk of developing a fragility fracture. J Bone Joint Surg Br. 2012; 94:1313–1320.

9. Lee YK, Ha YC, Park C, et al. Bisphosphonate use and increased incidence of subtrochanteric fracture in South Korea: results from the National Claim Registry. Osteoporos Int. 2013; 24:707–711.

10. Reid IR. Cardiovascular effects of calcium supplements. Nutrients. 2013; 5:2522–2529.

11. Bolland MJ, Grey A, Reid IR. Calcium supplements and cardiovascular risk in the Women's Health Initiative. Osteoporos Int. 2013; 24:2371–2372.

12. Korthoewer D, Chandran M. Osteoporosis management and the utilization of FRAX(R): a survey amongst health care professionals of the Asia-Pacific. Arch Osteoporos. 2012; 7:193–200.

13. Lee YK, Ha YC, Choi HJ, et al. Bisphosphonate use and subsequent hip fracture in South Korea. Osteoporos Int. 2013; 24:2887–2892.

14. Lewiecki EM, Baim S, Binkley N, et al. Report of the International Society for Clinical Densitometry 2007 Adult Position Development Conference and Official Positions. South Med J. 2008; 101:735–739.

15. Ohtera K, Ishii S, Matsuyama T. Influence of the vitamin D receptor alleles on human osteoblast-like cells. J Bone Joint Surg Br. 2001; 83:134–138.

16. Nuti R, Martini G, Valenti R, et al. Vitamin D status and bone turnover in women with acute hip fracture. Clin Orthop Relat Res. 2004; 208–213.

17. Sakuma M, Endo N, Oinuma T, et al. Vitamin D and intact PTH status in patients with hip fracture. Osteoporos Int. 2006; 17:1608–1614.

18. Hwang YC, Ahn HY, Jeong IK, et al. Optimal serum concentration of 25-hydroxyvitamin D for bone health in older Korean adults. Calcif Tissue Int. 2013; 92:68–74.

19. Lips P, Hosking D, Lippuner K, et al. The prevalence of vitamin D inadequacy amongst women with osteoporosis: an international epidemiological investigation. J Intern Med. 2006; 260:245–254.

20. National Osteoporosis Foundation. Physician's guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation;2003.

21. Javid KS, Thien A, Hill R. Implementation of and compliance with NICE guidelines in the secondary prevention of osteoporotic fractures in postmenopausal women. Ann R Coll Surg Engl. 2008; 90:213–215.

22. American Association of Clinical Endocrinologists. AACE Clinical Practice Guidelines for the Prevention and Treatment of Postmenopausal Osteoporosis. J Fla Med Assoc. 1996; 83:552–566.

23. Abrahamsen B, Eiken P, Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res. 2009; 24:1095–1102.

24. Black DM, Kelly MP, Genant HK, et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med. 2010; 362:1761–1771.

25. Schilcher J, Michaelsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med. 2011; 364:1728–1737.

26. Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the american society for bone and mineral research. J Bone Miner Res. 2014; 29:1–23.

27. McClung M, Harris ST, Miller PD, et al. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med. 2013; 126:13–20.

28. Compston J, Bowring C, Cooper A, et al. Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. Maturitas. 2013; 75:392–396.

29. Boonen S, Vanderschueren D, Haentjens P, et al. Calcium and vitamin D in the prevention and treatment of osteoporosis - a clinical update. J Intern Med. 2006; 259:539–552.

30. Nowson CA. Prevention of fractures in older people with calcium and vitamin D. Nutrients. 2010; 2:975–984.

31. Simonelli C, Killeen K, Mehle S, et al. Barriers to osteoporosis identification and treatment among primary care physicians and orthopedic surgeons. Mayo Clin Proc. 2002; 77:334–338.